UCB SA (OTCMKTS:UCBJF – Get Free Report) hit a new 52-week high during trading on Tuesday . The stock traded as high as $194.76 and last traded at $194.76, with a volume of 0 shares trading hands. The stock had previously closed at $194.76.
UCB Price Performance
The business’s 50-day moving average is $181.53 and its 200-day moving average is $157.20. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- Using the MarketBeat Dividend Yield Calculator
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
